In CNS5 WHO, some tumor molecular features (such as IDH1/2 mutation, TERT promoter mutation, EGFR amplification, H3 mutation, +7/−10, 1p/19q-codeletion, CDKN2A/B homozygous deletion, etc.,) that significantly impact on the prognosis of glioma have been further integrated and directly included in the diagnosis [4]. This evidence concerns the gene IDH1 and central nervous system cancer.